Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr Wagar on the Evolution of Advanced/Recurrent Endometrial Cancer Management

March 12th 2025

Matthew Wagar, MD, discusses how the management of advanced and recurrent endometrial cancer has evolved in recent years.

Dr Salani on Novel Trial Designs and Therapies in Gynecologic Malignancies

March 11th 2025

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.

Versamune HPV–Based Immunotherapy Combo Demonstrates Benefit in Advanced HPV-Associated Cancers

March 6th 2025

Versamune HPV plus PDS01ADC and bintrafusp alfa demonstrated clinical benefit in locally advanced or metastatic HPV-associated cancers.

Immunotherapy Continues to Redefine Treatment Considerations in Advanced/Recurrent Endometrial Cancer

March 6th 2025

Matthew Wagar, MD, discusses treatment considerations for advanced/recurrent endometrial cancer.

Dr Wagar on Lenvatinib Plus Pembrolizumab vs Chemo in First-Line Advanced Endometrial Cancer

March 5th 2025

Matthew Wagar, MD, discusses lenvatinib plus pembrolizumab vs chemotherapy as first-line treatment for advanced endometrial cancer.

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

March 5th 2025

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer

February 21st 2025

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.

Dr Pothuri on the Current Treatment Paradigm in Endometrial Cancer

February 14th 2025

Bhavana Pothuri, MD, discusses the current treatment paradigm in endometrial cancer and the targeted therapies currently being investigated.

Dr Wagar on the Role of Adjuvant Immunotherapy in Endometrial Cancer

February 13th 2025

Matthew Wagar, MD, discusses the use of adjuvant immunotherapy in endometrial cancer and the importance of accurate staging in optimizing outcomes.

2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward

February 13th 2025

Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.

Open Surgery Approaches and Sequencing Considerations Represent Core Parts of the Shifting Cervical Cancer Field

February 12th 2025

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings.

Short-Course Radiation Therapy Effective for Endometrial Cancer Patients

February 12th 2025

Short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

Pembrolizumab Provides Clinical Benefit in Previously Treated Advanced Clear Cell Gynecologic Cancer

February 9th 2025

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer

February 5th 2025

The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors

February 5th 2025

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Dr Chase on the Importance of QOL and PRO Measures in Gynecologic Oncology

February 1st 2025

Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.

Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer

February 1st 2025

A retrospective analysis showed a high proportion of endometrial cancer samples expressed FRα or B7-H4.

Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers

January 31st 2025

Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.

High-Grade Cancer, But Not SVM, Is Associated With OS Disparities in Black Patients With Uterine Carcinoma

January 31st 2025

High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.